__NUXT_JSONP__("/drugs/Monoclonal_Antibody_TRK-950", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A proprietary monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Although the mechanism of action has not been elucidated presumably monoclonal antibody TRK-950 binds to a specific TAA on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This may lead to the death of tumor cells expressing the TAA.",fdaUniiCode:"L1R0M8P1GD",identifier:"C142826",preferredName:c,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C20401"],synonyms:[c,"TRK 950","TRK-950"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FMonoclonal_Antibody_TRK-950",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Monoclonal_Antibody_TRK-950","Monoclonal Antibody TRK-950","2021-10-30T13:32:32.843Z")));